The evidence leans constructive8 supporting, 2 against, 0 worth knowing
Supporting
trading 34% above its 200-day average
sitting at 91% of its 52-week range, with little overhead supply from trapped buyers
up 33% over twelve months
matches growth that is speeding up, which has beaten the market by +0.79 points over 20 sessions across 57,921 past signals
6 of the scans it matches have a positive measured record
4 independent kinds of evidence agree today, which is uncommon
revenue grew 68% year on year in the quarter ending 30 June 2026
net margin has widened from 24.6% to 27.4% across four quarters
Against
1 of the scans it matches has historically underperformed the market
priced at 47× earnings against an industry median of 23× — 106% above its peers
Worth knowing
nothing the data supports either way
What would change this read: a close below 296, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working6
Revenue rose 67.8% year on year, from Rs 511 cr to Rs 858 cr.
+67.8%Rs 511 crRs 858 cr
Net profit rose 79.9% year on year, from Rs 131 cr to Rs 235 cr.
+79.9%Rs 131 crRs 235 cr
Profit rose year on year in all 4 of the last 4 quarters.
4
Trading 34.4% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+34.4%
Up 33.3% over the past year.
+33.3%
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching
Nothing on this side tonight — not in the filings and not in the price.
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
9 of 47 matched on 10 Sep
ACMESOLAR matches 9 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
ACMESOLAR trades at 47× trailing earnings, close to its median of 44× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Order win filings were typically -0.10pt vs the market over the next 5 sessions (n=630) · Capacity / capex filings were typically +0.33pt vs the market over the next 5 sessions (n=74)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 68% against the same quarter a year earlier
profit rose 80% year on year
net margin widened from 25.2% to 27.4%
revenue rose in 3 of the last 4 quarters
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
858
331
235
3.71
27.4%
Q4 FY26
31 Mar · consolidated
548
190
138
2.30
25.2%
Q3 FY26
31 Dec · consolidated
497
156
114
1.88
22.9%
Q2 FY26
30 Sep · consolidated
468
156
115
1.90
24.6%
Q1 FY26
30 Jun · consolidated
511
174
131
2.16
25.6%
Q4 FY25
31 Mar · consolidated
487
166
122
2.15
25.1%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+3.9%
Versus 200-day average+34.4%
Below 52-week high-5.0%
Above 52-week low+99.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)47.7
Higher closes in last 51 of 5
Six-month return+59.74%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)4.25%
Volume versus 20-day0.3x
Median daily turnoverRs 58.7 cr
Peers
Power · 21 classified companies
ACMESOLAR trades at 46.5× trailing earnings against an industry median of 22.6× across 19 other classified companies in its industry — more expensive than them, by 106%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.